• Assessment of overall survival and disease free survival of stage 1 endometrial cancer patients referred to the department of clinical oncology of Golestan Hospital in Ahvaz between 1395 and 1398
  • Fatemeh Mohammadian,1,* Negar Fazeli,2 Sasan Razmjoo,3 SeyedehHadis Sajjadi,4 Asma Yousefi Nezhad,5 Elaheh Mehraban,6
    2. Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
    3. Department of Clinical Oncology at Golestan Hospital and Cancer Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
    4. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
    5. Student Research Committee, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.


  • Introduction: The final results of the PORTEC-3 trial demonstrated that the combination of chemotherapy and radiotherapy, as an adjuvant treatment in high-risk patients, did not confer a significant benefit in overall survival. However, it did improve 5-year failure-free survival compared to radiotherapy alone. Consequently, this study aims to evaluate overall survival (OS) and recurrence-free survival (RFS) in stage I endometrial cancer patients, alongside assessing the differential rates of local versus systemic recurrence, stratified by the administration or omission of adjuvant therapy. The objective is to leverage the efficacy profile of each treatment modality to preclude the application of superfluous interventions, thereby mitigating the associated financial burden on individuals, families, and society at large. A further aim is to identify a patient cohort for whom clinical follow-up alone, without adjuvant treatment, is a viable management strategy. Should a statistically significant association with reduced recurrence or improved survival be established, the findings will inform necessary strategic planning for the effective implementation of these treatment paradigms.
  • Methods: This study will be conducted with the aim of evaluating the overall survival and disease-free survival of stage one endometrial cancer in patients of Golestan Hospital in Ahvaz between 1395 and 1398. The studied patients are women with stage one endometrial cancer who have only undergone hysterectomy or have undergone oncological treatments after total hysterectomy. The information of the patients, including age, date of diagnosis, date of starting treatment, type of pathology, stage, grade, treatment plans, information of death and recurrence, were extracted from their files. All analyzes were performed using SPSS version 22 software.
  • Results: The overall survival rate and 3- and 5-year disease-free survival rates of women with stage I endometrial cancer were lower in patients who received only chemotherapy or chemotherapy combined with radiotherapy, and the highest survival rate was in the group that received only EBRT or had received CT along with VBT and statistically the survival difference between these groups was significant (p<0.05).
  • Conclusion: Based on the results obtained in this study, patients who received external beam radiotherapy and combined chemotherapy with vaginal brachytherapy had a disease-free survival and overall survival of 100%.
  • Keywords: endometrium, cancer, survival, oncology